Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer.

Rupert Bartsch; Catharina De Vries; Ursula Pluschnig; Peter Dubsky; Zsuzsanna Bago-Horvath; Simon Peter Gampenrieder; Margaretha Rudas; Robert M Mader; Andrea Rottenfusser; Christoph Wiltschke; Michael Gnant; Christoph C Zielinski; Guenther G Steger

doi:10.1186/1471-2407-9-367

Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer.

Rupert Bartsch
, Catharina De Vries
, Ursula Pluschnig
, Peter Dubsky
, Zsuzsanna Bago-Horvath
, Simon Peter Gampenrieder (Co-author)
, Margaretha Rudas
, Robert M Mader
, Andrea Rottenfusser
, Christoph Wiltschke
, Michael Gnant
, Christoph C Zielinski
, Guenther G Steger

Research output: Contribution to journal › Original Article › peer-review

19 Citations (Web of Science)

Original language	English
Pages (from-to)	367
Journal	BMC CANCER
Volume	9
DOIs	https://doi.org/10.1186/1471-2407-9-367
Publication status	Published - 2009

Keywords

METASTATIC BREAST
MONOCLONAL-ANTIBODY
PHASE-II
SAFETY
EFFICACY
DISEASE
CAPECITABINE
CHEMOTHERAPY
PROGRESSION
RECEPTORS

Access to Document

10.1186/1471-2407-9-367

Cite this

@article{c59bcc065ae6412aa76d44432625b5df,

title = "Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer.",

keywords = "METASTATIC BREAST, MONOCLONAL-ANTIBODY, PHASE-II, SAFETY, EFFICACY, DISEASE, CAPECITABINE, CHEMOTHERAPY, PROGRESSION, RECEPTORS",

author = "Rupert Bartsch and \{De Vries\}, Catharina and Ursula Pluschnig and Peter Dubsky and Zsuzsanna Bago-Horvath and Gampenrieder, \{Simon Peter\} and Margaretha Rudas and Mader, \{Robert M\} and Andrea Rottenfusser and Christoph Wiltschke and Michael Gnant and Zielinski, \{Christoph C\} and Steger, \{Guenther G\}",

year = "2009",

doi = "10.1186/1471-2407-9-367",

language = "English",

volume = "9",

pages = "367",

journal = "BMC CANCER",

issn = "1471-2407",

publisher = " BioMed Central",

}

TY - JOUR

T1 - Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer.

AU - Bartsch, Rupert

AU - De Vries, Catharina

AU - Pluschnig, Ursula

AU - Dubsky, Peter

AU - Bago-Horvath, Zsuzsanna

AU - Gampenrieder, Simon Peter

AU - Rudas, Margaretha

AU - Mader, Robert M

AU - Rottenfusser, Andrea

AU - Wiltschke, Christoph

AU - Gnant, Michael

AU - Zielinski, Christoph C

AU - Steger, Guenther G

PY - 2009

Y1 - 2009

KW - METASTATIC BREAST

KW - MONOCLONAL-ANTIBODY

KW - PHASE-II

KW - SAFETY

KW - EFFICACY

KW - DISEASE

KW - CAPECITABINE

KW - CHEMOTHERAPY

KW - PROGRESSION

KW - RECEPTORS

U2 - 10.1186/1471-2407-9-367

DO - 10.1186/1471-2407-9-367

M3 - Original Article

C2 - 19835621

SN - 1471-2407

VL - 9

SP - 367

JO - BMC CANCER

JF - BMC CANCER

ER -